Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis
Annals of Hematology · 2026
DOI: 10.1007/s00277-026-07151-5 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Hematology, 2026. Verfasst von Nihal Babiker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Zagazig University, Zagazig, Egypt. Hauptthemen laut MEDLINE: beta-Thalassemia, Recombinant Fusion Proteins, Immunoglobulin Fc Fragments, Activin Receptors, Type II. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
β-thalassaemia is a genetic blood disorder characterized by ineffective erythropoiesis and chronic anaemia, often requiring lifelong red blood cell (RBC) transfusions. Luspatercept, an erythroid maturation agent, has emerged as a potential therapy to reduce transfusion burden in affected adults. To assess the clinical efficacy and safety of luspatercept in managing adult patients with β-thalassemia. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating luspatercept in adult patients with β-thalassemia. A comprehensive search of PubMed, Scopus, Embase, Cochrane Library, and ClinicalTrials.gov was performed for studies published up to May 2025. Only English-language RCTs were included. Data were extracted on transfusion burden, hemoglobin response, and adverse events. Risk of bias was assessed using the Cochrane ROB 2 tool. Pooled estimates were calculated using a random-effects model with the Freeman–Tukey double arcsine transformation. Heterogeneity was assessed using the I² statistic. Out of 587 identified records, three RCTs and one single-arm trial ( n = 608 patients) met the inclusion criteria. Of these, 447 patients received luspatercept and 161 received placebo. Luspatercept was associated with a ≥ 33% reduction in RBC transfusion burden in 58% (95% CI: 0.33–0.79) and a ≥ 50% reduction in 40% (95% CI: 0.25–0.58) of patients. Transfusion independence was achieved in 36% (95% CI: 0.13–0.69). Common adverse events included headache (32%), bone pain (33%), arthralgia (22%), and back pain (20%). Grade ≥ 3 adverse events occurred in 21% (95% CI: 0.09–0.41). Overall, luspatercept effectively reduced transfusion needs with an acceptable safety profile. Luspatercept significantly reduces transfusion burden in patients with β-thalassemia and demonstrates a manageable safety profile. These findings support luspatercept as an effective and well-tolerated therapeutic option that meaningfully reduces transfusion burden, potentially decreasing iron overload and improving quality of life for patients with β-thalassemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Zagazig University, Zagazig, Egypt.
- Faculty of Medicine, Tanta University, Tanta, Egypt.
- Tanta University Hospitals, Tanta, Egypt.
- The MetroHealth System, Cleveland, OH, United States.
- King Edward Medical University, Lahore, Punjab, Pakistan.
- Zagazig University, Zagazig, Egypt.
Zitieren
APA
Babiker, N., Abady, E., Shahid, H., Rehman, W. U., Babker, F., Sarhan, M., El Azzazi, H., Mohamed, M. A. E., Javed, H. M. H., & Samadi, Y. (2026). Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07151-5
Vancouver
Babiker N, Abady E, Shahid H, Rehman WU, Babker F, Sarhan M, et al. Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis. Annals of Hematology. 2026. doi:10.1007/s00277-026-07151-5
BibTeX
@article{Babiker2026,
author = {Babiker, Nihal and Abady, Eslam and Shahid, Hafsa and Rehman, Wania Ur and Babker, Faris and Sarhan, Menna and El Azzazi, Hind and Mohamed, Mohamedelborae Abdalgafar Elimam and Javed, Hafiz Muhammad Hannan and Samadi, Yahya},
title = {Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-07151-5}
}
EUVIMED